Substances · Cannabinoids (Indazole carboxamides)
ADB-FUBINACA
- Preferred name
- ADB-FUBINACA
- IUPAC name
- N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide
- Parent CAS number (reference)
- 1185282-00-1
- Molecular formula
- C21H23FN4O2
- Molecular weight
- 382.4 g/mol
- InChIKey
- ZSSGCSINPVBLQD-GOSISDBHSA-N
- PubChem
- CID 58124399
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
ADBFUBINACA ADB FUBINACA
Verified Neurochemical & Toxicological Intelligence
ADB-FUBINACA (ADMB-FUBINACA)
Receptor Telemetry & Mechanism of Action
Originally patented by Pfizer in 2009 (WO 2009/106980-A2; patent CAS 1185282-00-1), ADB-FUBINACA acts as a sub-nanomolar **full agonist** at human CB1 (**Ki = 0.36 nM; EC50 = 0.98–1.2 nM**, Emax ~3x JWH-018 and **up to 140-fold more potent than Delta9-THC**) and CB2 receptors (**EC50 = 3.5 nM**). In vitro neurotoxicology studies (2025, PMID 40480473) show PGC-1alpha dysregulation and mitochondrial fragmentation in differentiating neurons, while clinical/autopsy cases link exposure to seizures, rhabdomyolysis, kidney damage, and fatal coronary arterial thrombosis.
Biotransformation & Active Metabolites
Human hepatocyte incubations identify 23 metabolites dominated by hydroxydimethylpropyl-, hydroxydehydrodimethylpropyl-, and hydroxylindazole-ADB-FUBINACA urinary biomarkers.
Temporal Pharmacokinetics
Almost immediate (10–15 second onset), compact (up to 60 minute) full-CB1 rush producing heavy physical immobilization and mood elevation at low microgram levels, escalating abruptly into paranoia, chest pain, convulsions, and coma if exceeded.
- Onset 10–15 seconds inhaled
- Peak Window 10–25 minutes inhaled
- Total Window up to 60 minutes inhaled (longer orally or in toxic exposures)
- Residual / Half-Life 1–4 hours of residual somnolence and memory impairment; rapidly and extensively metabolized hepatically, though formal human plasma half-life is unverified.
UP TO 140x THC POTENCY + FULL-AGONIST CARDIOTOXICITY: Although isolated drug-forum posts cited by Swedish public health authorities mentioned 0.5–1 mg (500–1,000 ug), forensic toxicology links sub-milligram/milligram exposures directly to coma, seizures, rhabdomyolysis, kidney damage, and fatal coronary thrombosis. Volumetric microgram measurement is strictly required.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
25–50 ug (0.025–0.05 mg — tentative microgram estimate)
Rapid onset of mild relaxation, sensory softening, and time slowing within 10–15 seconds.
Faint bodily warmth and mild pulse elevation.
50–125 ug (0.05–0.125 mg — tentative microgram estimate)
Warm cannabimimetic mood elevation, music immersion, and calm mental deceleration.
Dry mouth, red eyes, soft limb heaviness, and appetite increase.
125–250 ug (0.125–0.25 mg — tentative microgram estimate)
Intense 'stoned' sedation, strong time distortion, short-term memory loss, and altered perception.
Marked motor suppression, tachycardia, dizziness, and strong urge to lie down.
250–500 ug (0.25–0.50 mg — tentative microgram estimate)
Severe confusion, hallucinations, agitation, acute paranoid anxiety, and loss of memory.
Chest pain, hypertension, severe tachycardia, vomiting, fever, and abrupt somnolence.
500+ ug (0.50+ mg — forum-reported 0.5–1 mg range overlaps severe/fatal clinical poisonings)
Loss of consciousness / coma or severe agitated delirium.
Seizures, fever, cardiotoxicity, rhabdomyolysis, acute kidney damage, coronary arterial thrombosis, and death.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Synergistic coma, loss of airway protection during vomiting, and fatal respiratory/cardiac arrest.
ADB-FUBINACA carries documented coronary arterial thrombosis and cardiotoxic risk; co-ingesting stimulants triggers fatal myocardial ischemia, arrhythmias, and seizures.
Frequently co-detected in severe poisonings; additive full CB1 overstimulation precipitates rapid coma, convulsions, and rhabdomyolysis.
Elevated Hazard — Avoid
Triggers severe psychotic panic, delirium, and lowered seizure threshold.
Caution / Receptor Attenuation
Never apply to or mix with cannabis flower; creates lethal quantitative brackets hot-spots.
Structural Isomer & Sibling Comparison
ADB-FUBINACA (CB1 Ki = 0.36 nM, EC50 = 0.98–1.2 nM, 4-fluorobenzyl tail) sits just behind ADB-PINACA (EC50 0.52 nM) and 5F-MDMB-PINACA (EC50 0.59 nM) in potency—making it ~3.6–10x lower in EC50 than MDMB-4en-PINACA (4.3 nM) and ADB-BUTINACA (6.36–11.5 nM), and up to 140x stronger than botanical THC. Its smoked/inhaled duration is notably fast and compact (10–15 s onset, up to 60 min duration), which can tempt premature repeated exposure.
Physicochemical Stability & Storage
Physical Form: White neat crystalline solid or fine white powder (fusion/melting point 135–137 °C; NEVER supplied on sprayed herbs). · Soluble in DMSO and ethanol; practically insoluble in water.
High stability (remains stable for >315 days at 20 °C and >105 days at 4 °C / -20 °C); store dry, sealed, and protected from light.
Cross-Tolerance & Dependence Profile
Rapid CB1 downregulation and cross-tolerance with all cannabinoids; chronic exposure carries high dependence liability and preclinical evidence of neuronal mitochondrial dysfunction.
Codes on this card
Short meanings for the abbreviations printed with this substance.
CB₁ / CB₂
Cannabinoid receptors CB1 and CB2
CB1 and CB2 are the two cannabinoid receptors named on these cards. Papers usually discuss CB1 in the nervous system and CB2 more often in immune tissue. The number beside them is often a Ki in nanomoles.
EC₅₀ / IC₅₀
Halfway concentration
EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.
Kᵢ
Binding tightness in nanomoles
Ki says how tightly a compound sits on a receptor in a binding test. It is written in nanomoles per litre. A Ki of 1 nM means very tight binding in that experiment.
ratio
Selectivity ratio
A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.
CAS
CAS registry number
A CAS number is a passport number for one chemical entry in the CAS registry. The free base and a salt of the same parent usually have different CAS numbers.
IUPAC
IUPAC Name & Molecular Formula
The molecular formula counts how many atoms of each element sit in one molecule, while the IUPAC name is the systematic map showing exactly how those atoms are connected.
CID / InChIKey
PubChem CID & Standard InChIKey
PubChem CID is the catalog number in the U.S. National Library of Medicine chemistry database, and InChIKey is a 27-character digital fingerprint of the molecule's exact 3D structure.
1 mg / µg
Calibrated Physical Form (1 mg Tablets, µg Liquid, Crystal)
Milligram-scale benzodiazepines are supplied as 1 mg tablets (1 tablet = 1 mg), microgram lysergamides as dissolved liquid (µg), and standard compounds as pure crystal or powder.
Chemical Architecture & Structural Profile
ADB-FUBINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide) is a reference compound belonging to the Cannabinoids (Indazole carboxamides) class, characterized by the molecular formula C21H23FN4O2 and a molar mass of 382.4 g/mol. The parent molecule is indexed under CAS registry number 1185282-00-1 and in the NCBI PubChem database as CID 58124399 (Standard InChIKey: ZSSGCSINPVBLQD-GOSISDBHSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), ADB-FUBINACA is indexed within the Cannabinoids (Indazole carboxamides) structural group. Synthetic indazole carboxamide exhibiting high receptor affinity in in-vitro assays; requires calibrated micro-analytical balances and full dermal and respiratory protection. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- Riksdagen — Förordning (1999:58) om förbud mot vissa hälsofarliga varor — Sveriges riksdag (2026-11-12)